Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study (Q39806485)

14 September 2017

title

Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study (English)

1 reference

14 September 2017

1 reference

venous thromboembolism

1 reference

12

Jeffrey I Weitz

1 reference

14 September 2017

2

Walter Ageno

1 reference

14 September 2017

11

Shannon M Winters

1 reference

14 September 2017

Gary Raskob

1

1 reference

14 September 2017

Alexander T Cohen

3

1 reference

14 September 2017

Marjolein P A Brekelmans

4

1 reference

14 September 2017

Michael A Grosso

5

1 reference

14 September 2017

Annelise Segers

6

1 reference

14 September 2017

Guy Meyer

7

1 reference

14 September 2017

Peter Verhamme

8

1 reference

14 September 2017

Philip S Wells

9

1 reference

14 September 2017

Min Lin

10

1 reference

14 September 2017

Harry R Büller

13

1 reference

14 September 2017

publication date

22 March 2016

1 reference

14 September 2017

published in

The Lancet. Haematology.

1 reference

14 September 2017

volume

3

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

e228-36

1 reference

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Oral apixaban for the treatment of acute venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Apixaban for extended treatment of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2900023-5

7 January 2021

10.1016/S2352-3026(16)00023-5

Identifiers

DOI

1 reference

14 September 2017

1 reference